Navigation Links
Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Date:5/21/2013

OXFORD, England, May 22, 2013 /PRNewswire/ --

First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix' particle engineering platform

Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, has initiated a Phase 2 clinical study with PSX1002 that will assess its effect on lung function and the safety of a range of doses in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The first two groups of eight patients, from up to 40 patients being enrolled, have been dosed at the Medicines Evaluation Unit in Manchester, UK, where the study is being conducted under the supervision of Professor Dave Singh . Further details of the study are below.

PSX1002 is a novel formulation of glycopyrronium bromide (GB), a long-acting muscarinic antagonist (LAMA), that is being developed as a potential 'best-in-class' orally inhaled monotherapy for COPD.  PSX1002 was designed using Prosonix' proprietary particle engineering technology platform, which has enabled the Company to create, and initiate clinical studies with a simple suspension formulation of GB for delivery via a pressurised metered dose inhaler (pMDI) that does not require or contain any other extraneous carriers or functional excipients.

Dr Geoff Down , Prosonix Chief Medical Officer, added: "Glycopyrronium bromide appears to be particularly useful in reversing airway constriction in COPD patients, increasing airflow, relieving symptoms and improving quality of life. We look forward to the results in 2014."

David Hipkiss , CEO of Prosonix commented: "This trial with PSX1002 is a very exciting step for Prosonix as it marks the first ever
'/>"/>

SOURCE Prosonix
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
2. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
3. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
4. Applied Genetics Initiates Commercial Operation
5. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
6. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
7. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
8. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
9. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
10. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
11. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 Cellgen Diagnostics ... $200,000 to fund a corporate lab for its ... This development is a critical component in the ... to the implementation of personalized medicine – a ... medicine. , Indiegogo contributions will support Cellgen’s intent ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 Robin Williams’ ... disease can take on an individual. Symptoms range ... facial expression, problems swallowing and severe depression. Parkinson’s ... dying off of dopamine producing neurons of the brain. ... a disease that slowly and progressively gets worse, they ...
(Date:8/19/2014)... , Aug. 19, 2014 ... the addition of the "Spectroscopy Equipment ... report to their offering. ... for Spectroscopy Equipment and Accessories in US$ ... Spectroscopy (UV-Vis spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, ...
(Date:8/19/2014)... 2012, the European Union (EU) mandated use of the ICH-recommended ... – responding to the increasing need to understand and manage ... many regions, the main objectives of the PBRER are to:, ... of new or emerging information on the risks of a ... potential benefits of a drug; and , Allow ...
Breaking Biology Technology:Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... broad corporate changes are ... ... Board: AVNA) today reported financial results for its first,quarter ended March ... Company refocused its business model from managing the,development of a portfolio ...
... Technology Distributors ... 2007., PLEASANTON, Calif., May 19 Direct Medical ... distribution network covering all,of Russia. This partnership has resulted ... volume sales to a number of medical,providers in Russia., ...
... W. Freston Single Topic Conference Series for ... Gastroenterology ... (AGA) Foundation for Digestive Health and Nutrition (FDHN),announced a gift ... Fund within the AGA Foundation,s overall endowment.,Interest earned from The ...
Cached Biology Technology:Advance Nanotech Reports First Quarter 2008 Financial Results 2Advance Nanotech Reports First Quarter 2008 Financial Results 3Advance Nanotech Reports First Quarter 2008 Financial Results 4Advance Nanotech Reports First Quarter 2008 Financial Results 5Advance Nanotech Reports First Quarter 2008 Financial Results 6Advance Nanotech Reports First Quarter 2008 Financial Results 7Advance Nanotech Reports First Quarter 2008 Financial Results 8Advance Nanotech Reports First Quarter 2008 Financial Results 9Advance Nanotech Reports First Quarter 2008 Financial Results 10Direct Medical Systems Reaches Profitability in 2-1/2 Years, as a Result of Sales of the World's Smallest and Lightest Ultrasound System, the InNovaSound USB Ultrasound. 2Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation 2Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation 3Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation 4
(Date:8/20/2014)... chili pepper causes a burning spiciness that is irresistible ... chili pepper,s effect are using their findings to develop ... which can be caused by inflammation or other problems. ... being tested in clinical trials, in ACS, Journal ... explain that decades ago, scientists had pegged a compound ...
(Date:8/20/2014)... Women who are poor experience higher cortisol levels ... levels of the stress hormone, putting them at ... to a new research from the University of Colorado ... American Journal of Human Biology , is the ... directly to the socioeconomic status of their mothers during ...
(Date:8/20/2014)... North Carolina State University researchers have developed methods for ... monitoring the electrical signals moths use to control those ... of remotely-controlled moths, or "biobots," for use in emergency ... know whether we can control the movement of moths ... operations," says Dr. Alper Bozkurt, an assistant professor of ...
Breaking Biology News(10 mins):CU Denver researcher shows economic disparities impact infant health 2Research paves way for development of cyborg moth 'biobots' 2
... lives and livelihoods of some of the poorest people on ... the Times Higher Education awards ceremony in London, Dr Bhaskar ... and Civil Engineering received the Outstanding Engineering Research Team of ... in tackling the world,s worst case of ongoing mass poisoning ...
... mystery of how an abundance of fossils have been marvellously ... region of Africa has been solved by a team of ... They have established that an ancient wind brought life to ... of the dead. Sarah Gabbott, Jan Zalasiewicz and colleagues ...
... garden bird of many countries in Europe and Asia. ... it has long been known individuals vary considerably in their ... as "fast" or "proactive" are quick explorers and are ... The differences are at least in part genetically determined ...
Cached Biology News:Queen's life-saving research wins education 'Oscar' 2Bird-brained? Birds' personalities are correlated with their hormone levels 2